Deals, pipeline readouts and company news from across biotech and pharma.
The Nasdaq-listed company says Corexa Pharmacy's GLP-1 dispensing drove growth, and it has regained Nasdaq compliance and launched compounded peptides under an FDA enforcement discretion policy.
The cannabis company's unaudited results to 30 September 2026 show lower revenue, a smaller asset base and a continuing shareholders' deficit, despite fresh funding from convertible notes and a private placement.
The company formerly known as Cybin ended September 2026 with $171.1M in cash, up from March, after about $86M in net equity proceeds.
The company's nine-month MD&A says IMC Holdings, including Adjupharm, went to an entity controlled by chief executive Oren Shuster on 29 September 2026.
The US biotech posted about $0.7m in royalty revenue and $5.8m in cash, and plans a Q1 2027 close for its Santersus acquisition.
The company reported third-quarter 2026 revenue of $5.4 million, with AlterG up 18% while ReWalk exoskeleton sales declined during its shift away from direct sales.
The clinical-stage company says it will need substantial extra funding, while a Phase 1 trial supports a single fixed dose per visit of inhaled mebufotenin.
The company reports a $7.9M net loss for the quarter, clears its Oaktree balance and adds a Phase 2 IBS-D asset licensed from Cedars-Sinai.
The US company says payer coverage for its PSVT nasal spray has reached about two-thirds of covered lives, and its cash runway now extends into late 2028.
The US dermatology company also reports a customs ruling on its redesigned RhodoLED XL-C lamp and a new sNDA to widen the actinic keratosis label.
The cannabis operator's Q3 2026 loss stems from a $5.0M charge on acquiring Rogue EBC, while it holds guidance and awaits approvals for a New York deal.
Bavarian Nordic held its upgraded 2026 guidance of about DKK 6.1bn in revenue and a roughly 32% EBITDA margin, with travel vaccines offsetting a flat quarter overall.
At the 2026 AGM, Mesoblast's chair described a shift from research-led business to commercial focus, citing roughly US$115 million in fiscal 2026 net sales of Ryoncil.
Mesoblast says FY2026 net revenue reached US$115M in the first full year of US sales of Ryoncil, while its pipeline and label-expansion studies progressed.
Dr Gregory George will act as interim chief operating officer while Mesoblast aligns with the FDA on a BLA in LVAD patients and awaits Phase 3 back pain data.
The company formerly known as FSD Pharma reports a smaller loss for the nine months to September 2026, with cash near $3.6M and digital assets near $8.7M.
The Nasdaq-listed former biopharma company, now selling fire safety products in Malaysia, also reports an effective S-4 for its proposed Future NRG combination.
The OTCQB-listed niche generics maker reported higher revenue and operating income for the quarter to 30 September 2026, with net income of $17.3m attributable to common shareholders.
The US gene-editing company also launched a partner-funded Indian Mustard programme and cut nine-month operating cash use by about 19%, to $30.2 million.
The capsule endoscopy maker reported a $7.3M quarterly net loss, completed enrolment in its CapsoCam Colon study and raised about $17.8M net in September.
The blood purification company reports $9.7M quarterly revenue and a narrower operating loss, while it pursues FDA marketing authorization for DrugSorb-ATR and tries to rebuild German sales.
The ultrafiltration specialist reported flat third-quarter sales of $2.2 million, a higher gross margin and a 24% smaller operating loss, alongside a pediatric filing and two distribution deals.
The dermatology company's U.S. YCANTH revenue rose 57.9% year over year, while enrolment in the first of two pivotal common warts trials is finished.
The RNS System maker cut its full-year revenue outlook to $91–92 million while advancing Remote Care, an idiopathic generalised epilepsy amendment and a new adolescent study.
In its third-quarter MD&A, the company reported a deferred-interest loan extension to licensee Unbuzzd, a cancelled warrant, a larger equity stake and a Nasdaq-only listing.
The gene therapy developer says the FDA agreed the pivotal Phase 2 design for RP-A501 and that KRESLADI is commercially ready, with cash expected to last into Q3 2028.
In its fiscal 2026 results, Arrowhead reported growth in the US Redemplo launch for FCS and an sNDA for sHTG, with a US launch targeted for Q2 2027.
Anaptys posted $30.3 million in collaboration revenue for the September quarter, with a rectal cancer approval for Jemperli and a Delaware judgment and an FDA decision both approaching.
The RNAi company reported a $12.4M third-quarter loss and $247.7M in cash, alongside positive Phase 2 divesiran data in polycythemia vera and a pending acquisition by Merck KGaA.
The US biotech reported third-quarter results alongside the divestment, and said VIRAGE2 enrolment in metastatic pancreatic cancer should finish in the fourth quarter of 2026.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.